Skip to content

Observation of curative effect on Parkinson's constipation patients treated with Zhengchangsheng capsule

Observation of curative effect on Parkinson's constipation patients treated with Zhengchangsheng capsule

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014830
Enrollment
Unknown
Registered
2018-02-08
Start date
2018-02-22
Completion date
Unknown
Last updated
2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Parkinson's disease with constipation

Interventions

Case series:Oral treatment of Bacillus licheniformis

Sponsors

Beijing Friendship Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Any age and gender meet the diagnostic criteria of Parkinson's disease and the diagnostic criteria for chronic constipation. (1) Symptoms must include 2 or more of the following: 1) at least 25% of defecation is laborious; 2) at least 25% of defecation is dry globular or hard; 3) at least 25% of defecation may not be felt; 4) At least 25% of defecation has anorectal obstruction or obstruction. At least 25% of defecation requires manual help (E. g., using fingers to defecate, The defecation times of pelvic floor were less than 3 times / week; (2) There were few dilute stools in the absence of laxatives; (3) There was not enough evidence to diagnose irritable bowel syndrome. The symptoms appeared for at least 6 months before diagnosis, and the symptoms met the above criteria in the last 3 months. (4) understand the purpose and procedure of the experiment and volunteer to participate in the experiment, be willing to comply with the taboos and restrictions stipulated in the scheme, be able to fill out logs and questionnaires as required, and agree to sign a written informed consent.

Exclusion criteria

Exclusion criteria: 1) severe cardiovascular or cerebrovascular diseases, neurological or mental disorders, or other causes that cannot be studied in conjunction with cancer or AIDS; 2) patients with local intestinal lesions, intestinal obstruction, toxic megacolon, gastrointestinal tumors and other organic intestinal diseases; 3) patients who are known to be allergic or allergic to intestinal or excipient substances.

Design outcomes

Primary

MeasureTime frame
16srRNA;

Countries

China

Contacts

Public ContactTuo Houzhen

Beijing Friendship Hospital affiliated to Capital Medical University

Tuohzh@sina.cn+86 13610468301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026